VANGUARD GROUP INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$9,808,552
-2.9%
8,312,332
+16.1%
0.00%
Q2 2023$10,097,995
+3.5%
7,161,699
+10.1%
0.00%
Q1 2023$9,757,408
+36.6%
6,504,938
+6.5%
0.00%
Q4 2022$7,145,254
+6.2%
6,107,054
+2.6%
0.00%
Q3 2022$6,726,000
-28.5%
5,951,4930.0%0.00%
Q2 2022$9,403,000
+2.5%
5,951,493
-0.1%
0.00%
Q1 2022$9,173,000
-37.2%
5,956,931
-0.1%
0.00%
Q4 2021$14,606,000
-2.7%
5,961,655
+0.1%
0.00%
Q3 2021$15,011,000
-17.7%
5,956,634
-6.9%
0.00%
Q2 2021$18,236,000
+39.6%
6,398,815
+15.1%
0.00%
Q1 2021$13,066,000
+19.6%
5,560,056
-10.4%
0.00%
Q4 2020$10,926,000
+123.2%
6,207,734
+18.7%
0.00%
Q3 2020$4,896,000
+7.7%
5,228,057
+0.0%
0.00%
Q2 2020$4,547,000
+0.2%
5,226,958
-4.6%
0.00%
Q1 2020$4,537,000
-6.8%
5,479,708
+0.2%
0.00%
Q4 2019$4,866,000
-9.4%
5,467,900
-0.2%
0.00%
Q3 2019$5,368,0005,476,8670.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders